Memantine, amantadine, and L-deprenyl potentiate the action of L-DOPA in monoamine-depleted rats

This publication has 32 references indexed in Scilit:

• THE EFFECT OF ADDING AMANTADINE TO OPTIMUM L-DOPA DOSAGE IN PARKINSON'S SYNDROME
  Acta Neurologica Scandinavica, 2009
• Current Status of Dopamine Agonists in Parkinson??s Disease Management
  Drugs, 1993
• Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1992
• Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of parkinson: Differential role of D-1 and D-2 receptors
  Neurochemistry International, 1992
• Current Drug Therapy for Parkinson??s Disease
  Drugs & Aging, 1992
• An Interim Report of the Effect of Selegiline (L -Deprenyl) on the Progression of Disability in Early Parkinson’s Disease
  European Neurology, 1992
• Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study
  European Journal of Pharmacology: Molecular Pharmacology, 1991
• Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease
  Trends in Neurosciences, 1990
• Effect of amantadine on chlorpromazine and reserpine-induced behavioral depression in the mouse
  Neuroscience & Biobehavioral Reviews, 1989
• The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1975